BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.8 CNY | +5.66% |
|
+1.66% | +5.14% |
| May. 07 | China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% | MT |
| May. 07 | BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 13,026 | 18,778 | 15,051 | 9,535 | 14,786 |
| Enterprise Value (EV) 1 | 12,311 | 18,479 | 15,616 | 10,326 | 15,944 |
| P/E ratio | 106 x | 112 x | 61.2 x | 38.9 x | 72.9 x |
| Yield | 0.26% | 0.18% | 0.33% | 0.51% | 0.27% |
| Capitalization / Revenue | 25.9 x | 23.9 x | 14.3 x | 9.37 x | 12.5 x |
| EV / Revenue | 24.5 x | 23.5 x | 14.8 x | 10.2 x | 13.5 x |
| EV / EBITDA | 92.2 x | 86.9 x | 55.2 x | 38.2 x | 58.1 x |
| EV / FCF | -184 x | -76.5 x | -20.1 x | -20.2 x | -49.6 x |
| FCF Yield | -0.54% | -1.31% | -4.98% | -4.96% | -2.01% |
| Price to Book | 9.92 x | 13.1 x | 8.97 x | 4.35 x | 6.24 x |
| Nbr of stocks (in thousands) | 410,000 | 410,000 | 410,000 | 422,465 | 422,465 |
| Reference price 2 | 31.77 | 45.80 | 36.71 | 22.57 | 35.00 |
| Announcement Date | 4/9/20 | 3/22/21 | 4/15/22 | 4/24/23 | 4/27/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 407.5 | 503.2 | 785.4 | 1,052 | 1,017 | 1,180 |
| EBITDA 1 | 94.25 | 133.5 | 212.7 | 282.9 | 270.4 | 274.4 |
| EBIT 1 | 76.88 | 107.9 | 183.1 | 249.2 | 231.4 | 208.2 |
| Operating Margin | 18.87% | 21.45% | 23.31% | 23.68% | 22.74% | 17.65% |
| Earnings before Tax (EBT) 1 | 79.22 | 119.9 | 191.3 | 257.5 | 242.2 | 188.8 |
| Net income 1 | 73.2 | 111.1 | 169.9 | 244 | 239.6 | 202.5 |
| Net margin | 17.96% | 22.08% | 21.63% | 23.18% | 23.55% | 17.17% |
| EPS 2 | 0.2100 | 0.3000 | 0.4100 | 0.6000 | 0.5800 | 0.4800 |
| Free Cash Flow 1 | -81.18 | -66.86 | -241.7 | -778.1 | -511.7 | -321.2 |
| FCF margin | -19.92% | -13.29% | -30.77% | -73.93% | -50.3% | -27.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | 0.0820 | 0.0840 | 0.1200 | 0.1140 | 0.0960 |
| Announcement Date | 10/16/19 | 4/9/20 | 3/22/21 | 4/15/22 | 4/24/23 | 4/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 565 | 791 | 1,158 |
| Net Cash position 1 | 296 | 715 | 299 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 1.997 x | 2.925 x | 4.221 x |
| Free Cash Flow 1 | -81.2 | -66.9 | -242 | -778 | -512 | -321 |
| ROE (net income / shareholders' equity) | 12% | 10.7% | 12.3% | 15% | 10.6% | 7.44% |
| ROA (Net income/ Total Assets) | 6.86% | 5.88% | 7.04% | 6.49% | 3.79% | 2.69% |
| Assets 1 | 1,067 | 1,891 | 2,412 | 3,758 | 6,322 | 7,540 |
| Book Value Per Share 2 | 15.90 | 3.200 | 3.490 | 4.090 | 5.190 | 5.610 |
| Cash Flow per Share 2 | 4.270 | 1.380 | 0.8300 | 0.8200 | 2.790 | 2.360 |
| Capex 1 | 112 | 89.5 | 355 | 910 | 727 | 404 |
| Capex / Sales | 27.6% | 17.8% | 45.24% | 86.44% | 71.43% | 34.23% |
| Announcement Date | 10/16/19 | 4/9/20 | 3/22/21 | 4/15/22 | 4/24/23 | 4/27/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.14% | 2.04B | |
| +32.11% | 694B | |
| +29.39% | 593B | |
| -1.59% | 371B | |
| +19.96% | 331B | |
| +7.01% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.44% | 169B |
- Stock Market
- Equities
- 688166 Stock
- Financials BrightGene Bio-Medical Technology Co., Ltd.